Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

@article{Citrome2014VortioxetineFM,
  title={Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?},
  author={Leslie Citrome},
  journal={International journal of clinical practice},
  year={2014},
  volume={68 1},
  pages={60-82}
}
OBJECTIVE To describe the efficacy and safety of vortioxetine for the treatment of major depressive disorder (MDD). DATA SOURCES The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/, http://www.clinicaltrialsregister.eu and http://www.clinicaltrials.gov for the search terms 'vortioxetine' and 'Lu AA21004', and by obtaining posters presented at congresses. Product labelling provided additional information. STUDY SELECTION All available clinical… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Vortioxetine for depression in adults.

The Cochrane database of systematic reviews • 2017
View 2 Excerpts

Similar Papers

Loading similar papers…